Does C9769 require prior authorization?

No, C9769 does not require prior authorization (high confidence). Covered without prior authorization.

`C9769`, Cystourethroscopy, with insertion of temporary prostatic implant/stent with

HCPCS/CPT

No Prior Auth Required

Covered without prior authorization (high confidence)

Laboratory values as applicable (e.g., PSA measurements reported in many trials and used as a secondary outcome).
Imaging/angiographic documentation for PAE (prostatic arterial anatomy identification) and documentation of technical feasibility or reasons for technical failure.
Erectile and ejaculatory function assessment (IIEF-5 or IIEF-15, MSHQ, MSHQ-EjD, SHIM) where preservation of sexual function is a treatment goal.
Adverse event reporting classified by Clavien-Dindo grading (many studies used this to grade complications).

ICD-10 codes covered if selection criteria are met: N35.010 - N35.92 Urethral stricture
PAE can be considered in patients with hematuria of prostatic origin as a method of achieving cessation of bleeding. (Level of Evidence: D; strength of recommendation: strong)
Alpha adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin)
Aquablation (AquaBeam, water jet hydrodissection)
Hormonal manipulation (including finasteride, dutasteride, and dutasteride plus tamsulosin)
Interstitial laser coagulation of the prostate (ILCP)

AETNA-CPB-0079, Benign Prostatic Hyperplasia

BCBSIL-MED201.025, Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia

BCBSMT-MED201.025, Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia

BCBSNM-MED201.025, Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia

BCBSOK-MED201.025, Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia

Ask Backwork about documentation requirements, denial risks, or coverage in your state.